About Contact Us Careers

Chlamydia Market Size & Share, by Test Type (Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests); Route of Administration (Oral, Injectable); End-user (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 3579
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Chlamydia Market size was valued at USD 3.33 billion in 2024 and is expected to reach USD 9.73 billion by 2037, expanding at around 8.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of chlamydia is assessed at USD 3.57 billion.

The growth of the market can be attributed to the increasing prevalence chlamydia and other sexually transmitted diseases, and rise in demand for screening of the disease among people all around the world. According to the World Health Organization, each year, there are an estimated 376 million new infections with 1 of 4 STIs: chlamydia, gonorrhea, syphilis and trichomoniasis. Also, more than 1 million sexually transmitted infections (STIs) are acquired every day worldwide. Along with these, growing number of government initiatives and free diagnostic camps for spreading awareness about sexually transmitted infections is also predicted to be a significant factor driving market growth in the near future. Furthermore, favorable reimbursement policies for companies are evaluated to give impetus to research and development activities associated with the development of novel drugs, which in turn is projected to offer lucrative opportunities for market growth in the forthcoming years.

Chlamydia-Treatment-Market-
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Increasing Prevalence of Sexually Transmitted Diseases Globally
  • Rising Demand for Screening of the Disease

Challenges

  • Social Stigma Associated with STIs

Chlamydia Market: Key Insights

Report Attribute Details

Base Year

2024

Forecast Year

2025-2037

CAGR

8.6%

Base Year Market Size (2024)

USD 3.33 billion

Forecast Year Market Size (2037)

USD 9.73 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Chlamydia Segmentation

The market is segmented by test type into culture tests, nucleic acid amplification test (NAAT), direct fluorescent antibody test, serology tests, and others, out of which, the nucleic acid amplification test (NAAT) segment is anticipated to hold the largest share in the global Chlamydia market. This can be accounted to the high accuracy of the test in screening the disease. Apart from these, NAATs allow screening of large number of males and females using self-collected vaginal swabs or using urine without the requirement of a pelvic examination. Additionally, on the basis of route of administration, the oral segment is assessed to acquire the largest share over the forecast period owing to the non-invasive nature, ease of convenience, and cost-effectiveness of this type of route for drug administration.

Our in-depth analysis of the global Chlamydia market includes the following segments:

          By Test Type
  • Culture Tests
  • Nucleic Acid Amplification Test (NAAT)
  • Direct Fluorescent Antibody Test
  • Serology Tests
  • Others

         By Route of Administration
  • Oral
  • Injectable
  • Others

         By End User

 
  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Others
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Chlamydia Industry - Regional Synopsis

Asia Pacific industry is predicted to hold largest revenue share by 2037, on account of growing demand for medical screening and burgeoning need for raising awareness about STIs., on account of growing demand for medical screening and burgeoning need for raising awareness about STIs. In addition, rapid growth of biopharmaceutical industry and rising government support for improving the healthcare infrastructure are also anticipated to drive the region’s market growth in the future. Moreover, the market in North America is projected to grab the largest share during the forecast period ascribing to the high adoption rate of medical screening, high prevalence of STDs, and presence of a large number of pharmaceutical and biopharmaceutical companies in the region. As per the Centers for Disease Control and Prevention, in 2019, a total of 1,808,703 cases of Chlamydia trachomatis infection were reported, making it the most common notifiable condition in the United States for that year.

Chlamydia-Treatment-Market-Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Companies Dominating the Chlamydia Landscape

    • Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • GlaxoSmithKline Plc
    • AstraZeneca plc
    • Gilead Sciences Inc.
    • Sanofi Group
    • Teva Pharmaceuticals
    • Novartis AG
    • Abbott Laboratories
    • Hologic, Inc.
    • Johnson & Johnson Services, Inc.

Recent Developments

  • October 2019- GSK began the phase III clinical program for new chemical class of antibiotic, gepotidacin, in patients with uncomplicated urinary tract infection and STDs.

  • August 2019- Statens Serum Institut, completed the clinical phase 1 trial for first-generation vaccine candidate (CTH522), which is aimed to provide a preventive therapy for chlamydia infection.

  • Report ID: 3579
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of chlamydia is assessed at USD 3.57 billion.

Chlamydia Market size was valued at USD 3.33 billion in 2024 and is expected to reach USD 9.73 billion by 2037, expanding at around 8.6% CAGR during the forecast period i.e., between 2025-2037.

Asia Pacific industry is predicted to hold largest revenue share by 2037, on account of growing demand for medical screening and burgeoning need for raising awareness about STIs.

The major players in the market are Pfizer, Inc., GlaxoSmithKline Plc, AstraZeneca plc, Gilead Sciences Inc., Sanofi Group, and others.

Chlamydia Treatment Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos